The bill, which was signed into law Wednesday, is created to protect transgender and LGBT individuals in hospitals, assisted living facilities, long-term care facilities, and retirement homes from discrimination and ensure their needs are met, such as letting them use the bathroom of their preferred gender. Ed Hernandez, D-West Covina, last month when the measure was approved by the Legislature.
Additional reporting requirements include requiring health plans and insurers to annually report specified information to regulators related to the proportion of the premium dollar spent on prescription drugs, the year-over-year increase in net costs and member costs, the 25 most frequently prescribed medications, most costly drugs by total plan spending, and drugs with the highest year over year increase in net cost. "That is the cost of prescription drugs".
The governor also signed a law that extends access to carpool lanes through fall 2025 for some alternative fuel vehicles with only a single occupant.
"It is disappointing that Gov".
"There is no evidence that SB 17 will lower drug costs for patients because it does not shed light on the large rebates and discounts insurance companies and pharmacy benefit managers (PBMs) are receiving that are not always being passed on to patients".
"No longer will pharmaceutical companies get to spike our prescription prices by double digits without advance notice or explanation". "So they are not the only piece of the drug supply chain, but they are the key piece to this".
Advocates, on the other hand, praised the governor's decision.
More than 2.3 million undocumented immigrants in California are now officially protected under a new state sanctuary law.
Beginning October 1, 2018, the California Office of Statewide Health Planning and Development [official website] will be required to collect data from manufacturers and report to the California Research Bureau [official website] specified changes in manufacturing and distribution, including increased drug prices. Industry watchers saw it as a victory for pharma and a big setback for pricing activists, but now a separate pricing regulation is in play not even one year later.
"The drug that I take, I take an MS disease modifying drug as everyone with MS is encouraged to do", Fargo said after the bill signing ceremony, "just a few years ago these drugs were about $10,000 a year, the drug I take is now $91,000 a year". If he does, the new law would bar branded drugmakers from attempting to preserve market share by lowering out-of-pocket costs to patients.